Protective Effects of Recombinant Zoster Vaccine and Antiviral Therapy Against Cardiovascular Disease Following Herpes Zoster Infection.

ABSTRACT:

Background

Herpes zoster (HZ) is associated with a higher risk of cardiovascular events, but the effect of the recombinant zoster vaccine (RZV) on this risk, alone or in combination with antiviral treatment, remains uncertain. The aim of this study was to evaluate the impact of RZV on the risk of cardiovascular disease (CVD) events following HZ infection.

Methods

We conducted a retrospective cohort study using the Optum Labs Data Warehouse. Adults aged ≥50 years with HZ diagnosed between 1 January 2018 and 31 March 2023 were included. Participants were categorized by their receipt of RZV and antiviral treatment for HZ. A Cox multivariable proportional hazards model estimated the association with post-HZ cardiovascular events.

Results

Among 112 637 patients with HZ, 52

SUBMITTER: Xu X 

PROVIDER: S-EPMC12687863 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature